CD19 and myositis disease: For example, a patient with refractory myositis showed complete remission, with improved muscle strength, lung function, and normalized autoantibodies and cytokines, using CD19-CAR T cells alongside mycophenolate mofetil to suppress CD8+ T cell–driven pathology [70].